A urinary microRNA signature can predict the presence of bladder urothelial carcinoma in patients undergoing surveillance

British Journal of Cancer

Volumn 114, Issue 4, 2016, Pages 454-462

  Sapre, Nikhil ^a   Macintyre, Geoff ^a   Clarkson, Michael ^a   Naeem, Haroon ^a   Cmero, Marek ^a   Kowalczyk, Adam ^a   Anderson, Paul D ^a   Costello, Anthony J ^a   Corcoran, Niall M ^a   Hovens, Christopher M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

biomarker; bladder cancer; genomics; microRNA; microRNA profiling; surveillance; tumour recurrence; urine

Indexed keywords

MICRORNA; TUMOR MARKER;

ARTICLE; BLADDER CARCINOMA; CANCER GRADING; CANCER PATIENT; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; CYSTOSCOPY; HUMAN; HUMAN TISSUE; MACHINE LEARNING; MAJOR CLINICAL STUDY; MORBIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SUPPORT VECTOR MACHINE; TUMOR RECURRENCE; URINE LEVEL; CASE CONTROL STUDY; PATHOLOGY; PROCEDURES; PROGNOSIS; URINARY BLADDER NEOPLASMS; URINE;

BIOMARKERS, TUMOR; CASE-CONTROL STUDIES; COHORT STUDIES; CYSTOSCOPY; HUMANS; MICRORNAS; PROGNOSIS; URINARY BLADDER NEOPLASMS;

EID: 84955557956     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.472     Document Type: Article

References (46)

1. Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, Mcconkey D, Bar-Eli M, Dinney C. (2009). miR-200 expression regulates epithelial-To-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res. 15: 5060-5072.
2. Avritscher EB, Cooksley CD, Grossman HB, Sabichi AL, Hamblin L, Dinney CP, Elting LS. (2006). Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology. 68: 549-553.
3. Bartsch G, Mitra AP, Cote RJ. (2010). Expression profiling for bladder cancer: strategies to uncover prognostic factors. Expert Rev Anticancer Ther. 10: 1945-1954.
4. Benjamini YAH. (1995). Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc. 57: 289-300.
5. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R. (2003). The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics. 21: 1315-1330.
6. Burk U, Schubert J, Wellner U, Schmalhofer O, Vincan E, Spaderna S, Brabletz T. (2008). A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells. EMBO Rep. 9: 582-589.
7. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, Hamdy FC, Kallioniemi O, Mengual L, Schlomm T, Visakorpi T. (2011). MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 59: 671-681.
8. Crawford NP, Walker RC, Lukes L, Officewala JS, Williams RW, Hunter KW. (2008). The Diasporin pathway: a tumour progression-related transcriptional network that predicts breast cancer survival. Clin Exp Metastasis. 25: 357-369.
9. Daniltchenko DI, Riedl CR, Sachs MD, Koenig F, Daha KL, Pflueger H, Loening SA, Schnorr D. (2005). Long-Term benefit of 5-Aminolevulinic acid fluorescence assisted transurethral resection of superficial bladder cancer: 5-year results of a prospective randomized study. J Urol. 174: 2129-2133; discussion 2133.
10. Dyrskjøt L, Kruhoffer M, Thykjaer T, Marcussen N, Jensen JL, Moller K, Orntoft TF. (2004). Gene expression in the urinary bladder: a common carcinoma in situ gene expression signature exists disregarding histopathological classification. Cancer Res. 64: 4040-4048.
11. Epstein JI, Amin MB, Reuter VR, Mostofi FK. (1998). The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol. 22: 1435-1448.
12. Fei DL, Sanchez-Mejias A, Wang Z, Flaveny C, Long J, Singh S, Rodriguez-Blanco J, Tokhunts R, Giambelli C, Briegel KJ, Schulz WA, Gandolfi AJ, Karagas M, Zimmers TA, Jorda M, Bejarano P, Capobianco AJ, Robbins DJ. (2012). Hedgehog signaling regulates bladder cancer growth and tumourigenicity. Cancer Res. 72: 4449-4458.
13. Garzon R, Calin GA, Croce CM. (2009). MicroRNAs in Cancer. Annu Rev Med. 60: 167-179.
14. Hanke M, Hoefig K, Merz H, Feller AC, Kausch I, Jocham D, Warnecke JM, Sczakiel G. (2010). A robust methodology to study urine microRNA as tumour marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer. Urol Oncol. 28: 655-661.
15. Hirata H, Ueno K, Shahryari V, Tanaka Y, Tabatabai ZL, Hinoda Y, Dahiya R. (2012). Oncogenic miRNA-182-5p targets Smad4 and RECK in human bladder cancer. PLoS One. 7: e51056.
16. Hong MK, Sapre N, Phal PM, Macintyre G, Chin X, Pedersen JS, Ryan A, Kerger M, Costello AJ, Corcoran NM, Hovens CM. (2014). Percutaneous image-guided biopsy of prostate cancer metastases yields samples suitable for genomics and personalised oncology. Clin Exp Metastasis. 31: 159-167.
17. Jansson MD, Lund AH. (2012). MicroRNA and cancer. Mol Oncol. 6: 590-610.
18. Katoh M. (2009). Transcriptional mechanisms of WNT5A based on NFkappaB, Hedgehog, TGFbeta, and Notch signaling cascades. Int J Mol Med. 23: 763-769.
19. Katoh M. (2012). Function and cancer genomics of FAT family genes (review). Int J Oncol. 41: 1913-1918.
20. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE. (2000). A prospective analysis of 1, 930 patients with hematuria to evaluate current diagnostic practice. J Urol. 163: 524-527.
21. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R, Salzberg SL. (2013). TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. Genome Biol. 14: R36.
22. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, Epstein EJ, Macmenamin P, Da Piedade I, Gunsalus KC, Stoffel M, Rajewsky N. (2005). Combinatorial microRNA target predictions. Nat Genet. 37: 495-500.
23. Kupfer P, Guthke R, Pohlers D, Huber R, Koczan D, Kinne RW. (2012). Batch correction of microarray data substantially improves the identification of genes differentially expressed in rheumatoid arthritis and osteoarthritis. BMC Med Genomics. 5: 23.
24. Langmead B, Trapnell C, Pop M, Salzberg SL. (2009). Ultrafast and memoryefficient alignment of short DNA sequences to the human genome. Genome Biol. 10: R25.
25. Lauss M, Ringner M, Hoglund M. (2010). Prediction of stage, grade, and survival in bladder cancer using genome-wide expression data: a validation study. Clin Cancer Res. 16: 4421-4433.
26. Lee JS, Leem SH, Lee SY, Kim SC, Park ES, Kim SB, Kim SK, Kim YJ, Kim WJ, Chu IS. (2010). Expression signature of E2F1 and its associated genes predict superficial to invasive progression of bladder tumours. J Clin Oncol. 28: 2660-2667.
27. Li Y, Zhang D, Chen C, Ruan Z, Huang Y. (2012). MicroRNA-212 displays tumour-promoting properties in non-small cell lung cancer cells and targets the hedgehog pathway receptor PTCH1. Mol Biol Cell. 23: 1423-1434.
28. Lo PK, Lee JS, Liang X, Han L, Mori T, Fackler MJ, Sadik H, Argani P, Pandita TK, Sukumar S. (2010). Epigenetic inactivation of the potential tumour suppressor gene FOXF1 in breast cancer. Cancer Res. 70: 6047-6058.
29. Lohse M, Bolger AM, Nagel A, Fernie AR, Lunn JE, Stitt M, Usadel B. (2012). RobiNA: a user-friendly, integrated software solution for RNA-Seq-based transcriptomics. Nucleic Acids Res. 40: W622-W627.
30. Miah S, Dudziec E, Drayton RM, Zlotta AR, Morgan SL, Rosario DJ, Hamdy FC, Catto JW. (2012). An evaluation of urinary microRNA reveals a high sensitivity for bladder cancer. Br J Cancer. 107: 123-128.
31. Mitra AP, Castelao JE, Hawes D, Tsao-Wei DD, Jiang X, Shi SR, Datar RH, Skinner EC, Stein JP, Groshen S, Yu MC, Ross RK, Skinner DG, Cortessis VK, Cote RJ. (2013). Combination of molecular alterations and smoking intensity predicts bladder cancer outcome: a report from the Los Angeles Cancer Surveillance Program. Cancer. 119: 756-765.
32. Mongroo PS, Rustgi AK. (2010). The role of the miR-200 family in epithelialmesenchymal transition. Cancer Biol Ther. 10: 219-222.
33. Quinlan AR, Hall IM. (2010). BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics. 26: 841-842.
34. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P, Varambally S, Ghosh D, Chinnaiyan AM. (2007). Oncomine 3.0: genes, pathways, and networks in a collection of. 18, 000 cancer gene expression profiles. Neoplasia. 9: 166-180.
35. Robinson MD, Mccarthy DJ, Smyth GK. (2010). edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 26: 139-140.
36. Sanchez-Carbayo M, Socci ND, Lozano J, Saint F, Cordon-Cardo C. (2006). Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays. J Clin Oncol. 24: 778-789.
37. Sangar VK, Ragavan N, Matanhelia SS, Watson MW, Blades RA. (2005). The economic consequences of prostate and bladder cancer in the UK. BJU Int. 95: 59-63.
38. Sapre N, Anderson PD, Costello AJ, Hovens CM, Corcoran NM. (2014). Gene-based urinary biomarkers for bladder cancer: an unfulfilled promise?. Urol Oncol. 32: 48 e9-17.
39. Schmidt WM, Uddin MH, Dysek S, Moser-Thier K, Pirker C, Hoger H, Ambros IM, Ambros PF, Berger W, Bittner RE. (2011). DNA damage, somatic aneuploidy, and malignant sarcoma susceptibility in muscular dystrophies. PLoS Genet. 7: e1002042.
40. Schrag D, Hsieh LJ, Rabbani F, Bach PB, Herr H, Begg CB. (2003). Adherence to surveillance among patients with superficial bladder cancer. J Natl Cancer Inst. 95: 588-597.
41. Su SF, De Castro Abreu AL, Chihara Y, Tsai Y, Andreu-Vieyra C, Daneshmand S, Skinner EC, Jones PA, Siegmund KD, Liang G. (2014). A panel of three markers hyper- And hypomethylated in urine sediments accurately predicts bladder cancer recurrence. Clin Cancer Res. 20: 1978-1989.
42. Sylvester RJ, Van Der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. (2006). Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 49: 466-475.
43. Veeck J, Chorovicer M, Naami A, Breuer E, Zafrakas M, Bektas N, Durst M, Kristiansen G, Wild PJ, Hartmann A, Knuechel R, Dahl E. (2008). The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation. Oncogene. 27: 865-876.
44. Wang G, Chan ES, Kwan BC, Li PK, Yip SK, Szeto CC, Ng CF. (2012). Expression of microRNAs in the urine of patients with bladder cancer. Clin Genitourin Cancer. 10: 106-113.
45. Yun SJ, Jeong P, Kim WT, Kim TH, Lee YS, Song PH, Choi YH, Kim IY, Moon SK, Kim WJ. (2012). Cell-free microRNAs in urine as diagnostic and prognostic biomarkers of bladder cancer. Int J Oncol. 41: 1871-1878.
46. Zudaire E, Cuesta N, Murty V, Woodson K, Adams L, Gonzalez N, Martinez A, Narayan G, Kirsch I, Franklin W, Hirsch F, Birrer M, Cuttitta F. (2008). The aryl hydrocarbon receptor repressor is a putative tumour suppressor gene in multiple human cancers. J Clin Invest. 118: 640-650.